+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 43 Actively Recruiting clinical trials

A

Actively Recruiting

Researchers are conducting a master protocol study called IIBD to evaluate the safety and effectiveness of new treatments for adults with moderately to severely active ulcerative colitis or Crohns disease. This phase 2, randomized, controlled study includes multiple individual sub-studies that share key design features. Participants are assigned to the appropriate sub-study before being randomized to a treatment group, with the overall study lasting at least 62 weeks. The study treatments include mirikizumab given intravenously IV during the first study period. Responders then receive mirikizumab subcutaneously SC in the second period. Another group will receive oral LY4395089 combined with IV mirikizumab initially, then responders stop LY4395089 and continue with mirikizumab SC. These two treatment approaches are being assessed in parallel groups. Participants will undergo screening to confirm diagnosis and disease activity, followed by regular study visits during the treatment periods. Researchers will monitor laboratory test results and evaluate response to treatment using measures such as the modified Mayo score for ulcerative colitis and the Crohns disease activity index. The primary outcome includes tracking the number of participants assigned to each treatment group up to day 42. The study runs through March 2028 with ongoing safety and efficacy assessments.

Age: 18Years - 80YearsAll GendersPhase 2
71 locations
R

Actively Recruiting

Researchers are evaluating a new approach to selecting biologic treatments for adults with active Crohns Disease CD. This prospective, randomized study compares standard treatment selection to a method guided by epigenetic markers, aiming to assess which method better induces clinical remission and improves endoscopic response. The trial includes patients who are either new to biologic therapy or have used no more than one prior biologic treatment. The study is designed to measure efficacy, safety, and cost-effectiveness of this epigenome-guided approach. Participants are randomly assigned to one of two groups one receives biologic therapy based on epigenetic testing results using a specialized software called EpiPredict, which predicts response to two biologics, Vedolizumab VDZ or Ustekinumab UST. The other group receives biologic treatment chosen by their doctor following usual care guidelines without epigenetic information. Both groups receive their biologic treatments as labeled, with dosing adjustments allowed as needed by the treating physician. Throughout the 26-week treatment phase, participants undergo clinical assessments aligned with their biologic treatment schedules. Follow-up visits continue every six months up to two years, collecting data from medical records and online questionnaires. Researchers will measure clinical remission, endoscopic response, and cost-effectiveness among other outcomes to determine the value of using epigenetic markers in treatment selection for Crohns Disease.

Age: 18Years +All GendersPhase Not Applicable
51 locations
E

Actively Recruiting

Researchers are evaluating the clinical effectiveness and safety of icotrokinra in adults with moderately to severely active Crohns disease, a long-term condition causing serious inflammation in the intestines. The study is a Phase 2b3 randomized, double-blind, placebo-controlled trial aiming to better understand how well icotrokinra works in treating this condition. Participants will receive one of several oral treatments daily during an initial 12-week induction phase either one of two doses of icotrokinra or a matching placebo. After Week 12, their response status will guide further treatment. Those responding to icotrokinra may be randomized to maintenance doses for up to 40 weeks, with some eligible to join a long-term extension study. Placebo recipients who respond may continue placebo or switch to icotrokinra under specific conditions. Throughout the trial, participants will undergo regular assessments to monitor clinical response, remission, and endoscopic healing at Weeks 12 and 40. Safety will be closely followed up to four weeks after the last dose. The study measures various outcomes including patient-reported remission, inflammatory markers, quality of life, and fatigue. Total participation may extend up to several months depending on treatment phase and eligibility for long-term follow-up.

Age: 18Years +All GendersPhase 2Phase 3
395 locations
E

Actively Recruiting

Researchers are evaluating the effectiveness and safety of JNJ-78934804 compared to guselkumab in adults with moderately to severely active Crohns disease, a long-term and progressive intestinal condition. This Phase 3 study aims to assess how well these treatments work by measuring clinical and endoscopic remission at Week 48. The study is sponsored by Janssen Research & Development, LLC. Participants are randomly assigned to receive either JNJ-78934804 or guselkumab, both given as subcutaneous injections. Treatment starts with induction doses at Weeks 0, 4, and 8, followed by maintenance doses every 4 weeks from Week 12 onward. Those meeting rescue criteria during the study may receive additional induction doses of JNJ-78934804 at Weeks 16, 20, and 24, then continue maintenance dosing from Week 28. After completing the double-blind phase at Week 48, participants who may benefit can join a long-term extension phase. During the study, participants will undergo assessments to measure clinical remission, endoscopic remission, and other outcomes like deep remission and corticosteroid-free remission at various time points. Researchers will monitor patient-reported outcomes, adverse events, and serious adverse events for up to approximately three years. The study involves regular evaluations of disease activity and safety to understand treatment effects and participant well-being over time.

Age: 18Years +All GendersPhase 3
287 locations
E

Actively Recruiting

Researchers are evaluating the efficacy and safety of JNJ-78934804 compared to guselkumab in adults with moderately to severely active ulcerative colitis, a chronic condition causing inflammation and ulcers in the colon lining. This phase 3, randomized, double-blind, active-controlled study aims to assess how well these treatments work by measuring clinical remission at Week 48. Participants receive either JNJ-78934804 or guselkumab through subcutaneous injections. Both treatments begin with induction doses at Weeks 0, 4, and 8, followed by maintenance doses every 4 weeks starting at Week 12. Participants who meet rescue criteria during the study may receive additional induction doses of JNJ-78934804 at Weeks 16, 20, and 24, with maintenance continuing every 4 weeks from Week 28. Those completing the initial 48-week treatment phase and deemed to benefit may join a long-term extension phase. Throughout the study, participants undergo assessments including endoscopic evaluations, clinical remission status, symptom scores, quality of life questionnaires, and safety monitoring for adverse events up to approximately 3 years. The primary outcome is the percentage of participants achieving clinical remission at Week 48, with multiple secondary outcomes measured at various time points. This comprehensive evaluation helps understand the treatment effects and safety profile over time.

Age: 18Years +All GendersPhase 3
318 locations
E

Actively Recruiting

Researchers are evaluating the safety and effectiveness of several investigational long-acting antibody treatments, both alone and in combination, for adults with moderately to severely active ulcerative colitis UC. This Phase 2 platform study involves multiple centers and aims to improve treatment options for this condition by comparing different therapies. The study consists of two parts. Part A was an open-label phase assessing safety and early effectiveness of three monotherapies, which completed enrollment in April 2026. Part B is currently enrolling and is a randomized, placebo-controlled phase testing three monotherapies and three combination therapies against placebo. Participants will receive intravenous induction and subcutaneous maintenance treatments, with different dosing regimens evaluated over time. Participants will be monitored through regular assessments including endoscopy and histology to measure disease activity and response. The main outcomes include clinical remission and histologic improvement after 12 weeks, with longer-term remission assessed up to 48 weeks. Safety and efficacy data will be collected throughout, with treatment duration and follow-up determined by study protocol. The total study completion is expected by March 2028.

Age: 18Years - 75YearsAll GendersPhase 2
276 locations
E

Actively Recruiting

Researchers are evaluating the safety and effectiveness of a drug called LY4395089, a farnesoid X receptor FXR agonist, when given together with mirikizumab compared to mirikizumab alone in adults with moderately to severely active Crohns disease. This Phase 2 study is part of the IIBD master protocol and is expected to last about 62 weeks. The goal is to better understand how this combination treatment works for this condition. Participants will be assigned to one of two groups one receiving only mirikizumab and the other receiving both LY4395089 orally and mirikizumab intravenously during the first study period. Responders will then stop LY4395089 and receive mirikizumab subcutaneously in the second study period. Mirikizumab is given first via IV and later by a subcutaneous injection. The study compares these treatment approaches to assess differences in response. During the study, participants will undergo assessments including endoscopic evaluation to measure response up to week 12, clinical remission checks, and fecal calprotectin tests to monitor inflammation levels. Researchers will track safety and efficacy throughout the approximately 62-week study duration. Participants will have regular visits for treatment administration and monitoring, with the main focus on the percentage of participants achieving endoscopic response by week 12.

Age: 18Years - 80YearsAll GendersPhase 2
71 locations
E

Actively Recruiting

This research focuses on adults with moderate-to-severe Crohns Disease CD, a chronic inflammatory condition of the digestive tract. It aims to evaluate how effective two approved drugs, upadacitinib and risankizumab, are as second-line treatments for CD in real-world clinical settings. Approximately 250 participants prescribed either drug by their physicians will be enrolled across 25 sites in Italy. Participants will receive either upadacitinib or risankizumab as part of their usual medical care, following local prescribing guidelines. The study includes a retrospective phase looking back up to 2 years before enrollment and a prospective phase where participants will be observed for up to 18 months after starting the medication. Both groups will be followed from their first dose throughout the study period. During this time, participants will not experience any additional study-related burden beyond their routine care. Researchers will review clinical records and monitor outcomes such as the percentage of participants achieving corticosteroid-free remission at 12 months. The study aims to gather real-world data on these treatments effectiveness and safety over time, with no extra visits or procedures required beyond standard practice.

Age: 18Years +All Genders
25 locations
E

Actively Recruiting

Researchers are evaluating the effectiveness and safety of induction therapy using Afimkibart also called RO7790121 in adults with moderately to severely active Crohns disease. This Phase III, multicenter, double-blind, placebo-controlled study aims to determine whether this treatment can induce clinical remission and improve endoscopic response compared to placebo. The trial is led by Hoffmann-La Roche and focuses on participants aged 16 to 80 years who have an inadequate response or intolerance to other Crohns disease treatments. Participants are randomly assigned to one of two groups one group receives Afimkibart initially through intravenous infusion followed by subcutaneous injections, while the other group receives a placebo intravenous infusion followed by Afimkibart subcutaneous injections. The study follows a parallel design with double-blinding to compare the effects of these treatment approaches over a 12-week induction period. During the trial, participants will undergo assessments including Crohns Disease Activity Index scoring, endoscopic evaluations, and symptom tracking such as stool consistency, abdominal pain, and fatigue. Researchers will monitor clinical remission, symptomatic relief, and adverse events up to 30 weeks after baseline. Quality of life will be measured with questionnaires, and biomarker subgroups will be analyzed. The studys total duration extends through 2033, with key measurements taken at week 12.

Age: 16Years - 80YearsAll GendersPhase 3
208 locations
E

Actively Recruiting

Researchers are evaluating the efficacy and safety of tulisokibart in people with moderately to severely active Crohns disease. This program includes two separate studies Study 1, which involves both induction and maintenance treatment phases, and Study 2, which includes only the induction treatment phase. The main goals are to see if one or more doses of tulisokibart are better than placebo in achieving clinical remission according to specific Crohns Disease Activity Index scores or stool frequency and abdominal pain scores, and to assess endoscopic response at weeks 12 and 52 depending on the study and regulatory region. Participants receive tulisokibart either intravenously or subcutaneously at different dose levels depending on the study arm. Some receive a high dose induction followed by high or low dose maintenance, others receive low dose throughout, and some receive placebo. Extension arms allow participants who complete their original treatment to continue receiving high or low dose subcutaneous tulisokibart if they qualify. The study uses random assignment to treatment groups and is double-blind, meaning neither participants nor researchers know who receives the drug or placebo. Throughout the studies, participants undergo evaluations at specified weeks to measure clinical remission, clinical response, endoscopic response, and other outcomes such as fatigue and quality of life. Safety is monitored by tracking adverse events and discontinuations due to side effects. The overall participation may last up to 52 weeks for Study 1 and 12 weeks for Study 2, with assessments at multiple points to carefully observe treatment effects and safety.

Age: 16Years - 80YearsAll GendersPhase 3
499 locations

1-10 of 43

1